Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy

Purpose: The aims of the present study were to examine the effects of intravesical instillation of epirubicin on tumor recurrence and to identify tumors that are at a high risk of recurrence.

[1]  H. Huland,et al.  Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival. , 1984, The Journal of urology.

[2]  I. Miyagawa,et al.  Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors , 2004, Cancer Chemotherapy and Pharmacology.

[3]  F. D. da Silva,et al.  4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer. , 1992, European urology.

[4]  S. Loening,et al.  Superficial bladder cancer: progression and recurrence. , 1983, The Journal of urology.

[5]  S. Kamidono,et al.  Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial , 2004, Cancer Chemotherapy and Pharmacology.

[6]  G. Barbalias,et al.  Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study. , 1992, The Journal of urology.

[7]  K. Kurth,et al.  Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. , 1991, The Journal of urology.

[8]  F. Ito,et al.  A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer , 2004, Cancer Chemotherapy and Pharmacology.

[9]  D. Newling,et al.  A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour. , 1990, European urology.

[10]  W. Taylor,et al.  Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. , 1985, The Journal of urology.

[11]  M. Melekos.  Prophylaxis of superficial bladder cancer with a modified intravesical epirubicin treatment schedule. , 1993, Oncology.

[12]  K. Kobashi.  [Statistical analysis of recurrent factors in superficial bladder cancer. Natural history of superficial bladder cancer]. , 1993, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[13]  W Lutzeyer,et al.  Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. , 1982, The Journal of urology.

[14]  S. Loening,et al.  Bladder cancer: factors affecting survival. , 1983, The Journal of urology.

[15]  R. J. Cersosimo,et al.  Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Catalona,et al.  Urothelial Tumors of the Urinary Tract , 1992 .

[17]  S. Nakagawa,et al.  Intravesical instillation of Adriamycin for bladder tumors , 2004, Cancer Chemotherapy and Pharmacology.

[18]  N. Sato,et al.  [Prognostic factors for progression of superficial bladder cancer]. , 1992, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[19]  T. Kakizoe,et al.  [Growth and progression patterns of papillary superficial bladder cancer]. , 1987, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology.

[20]  T. Shuin,et al.  A phase II study of prophylactic intravesical chemotherapy with 4′-epirubicin in recurrent superficial bladder cancer: comparison of 4′-epirubicin and Adriamycin , 2004, Cancer Chemotherapy and Pharmacology.

[21]  O. Dalesio,et al.  Prognostic factors in superficial bladder tumors. A study of the European Organization for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. , 1983, The Journal of urology.

[22]  M. Melekos,et al.  Intravesical 4′‐epi‐doxorubicin(epirubicin) versus bacillus calmette—guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer , 1993, Cancer.

[23]  T. Sakata,et al.  A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer , 2004, Cancer Chemotherapy and Pharmacology.

[24]  M. Siroky,et al.  Granulomatous prostatitis following bacillus Calmette-Guerin immunotherapy of bladder cancer. , 1988, The Journal of urology.

[25]  L. Baert,et al.  Chronic bacterial prostatitis: 10 years of experience with local antibiotics. , 1988, The Journal of urology.

[26]  S. Loening,et al.  Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. , 1983, The Journal of urology.